Terms: = Prostate cancer AND CD79A, ENSG00000105369, 973, P11912, MB-1, IGA AND Treatment
30 results:
1. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract] [Full Text] [Related]
2. Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
Pham J; Neilsen BK; Liu H; Cao M; Yang Y; Sheng K; Ma TM; Kishan AU; Ruan D
Med Phys; 2024 Jan; 51(1):612-621. PubMed ID: 38055353
[TBL] [Abstract] [Full Text] [Related]
3. A Nationwide Study of Differences in Surgical treatment Rates and Oncological Outcomes for prostate cancer according to Economic Status and Region.
Yoo S; Oh S; Cho MC; Son H; Jeong H
Cancer Res Treat; 2023 Apr; 55(2):652-658. PubMed ID: 36510653
[TBL] [Abstract] [Full Text] [Related]
4. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive prostate cancer.
Freeman MN; Jang A; Zhu J; Sanati F; Nandagopal L; Ravindranathan D; Desai A; Phone A; Nussenzveig R; Jaeger E; Caputo SA; Koshkin VS; Swami U; Basu A; Bilen MA; Agarwal N; Sartor O; Burgess EF; Barata PC
Oncologist; 2022 Mar; 27(3):220-227. PubMed ID: 35274720
[TBL] [Abstract] [Full Text] [Related]
5. Does the type of biopsy used for diagnosis impact subsequent treatment selection in prostate cancer patients?
Levin BA; Lama DJ; Sussman J; Guan T; Rao M; Tobler J; Verma S; Sidana A
Aging Male; 2022 Dec; 25(1):23-28. PubMed ID: 34983290
[TBL] [Abstract] [Full Text] [Related]
6. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis.
Shemshaki H; Al-Mamari SA; Geelani IA; Kumar S
Urologia; 2022 Feb; 89(1):16-30. PubMed ID: 34355602
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy.
Ohba K; Miyata Y; Mukae Y; Mitsunari K; Matsuo T; Sakai H
Can J Urol; 2021 Jun; 28(3):10706-10712. PubMed ID: 34129467
[TBL] [Abstract] [Full Text] [Related]
8. Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high-risk prostate cancer.
Kaps B; Leapman M; An Y
Cancer Med; 2020 Dec; 9(23):8754-8764. PubMed ID: 33128858
[TBL] [Abstract] [Full Text] [Related]
9. Identification of key genes and pathways in iga nephropathy using bioinformatics analysis.
Hu SL; Wang D; Yuan FL; Lei QF; Zhang Y; Cheng JZ
Medicine (Baltimore); 2020 Jul; 99(30):e21372. PubMed ID: 32791747
[TBL] [Abstract] [Full Text] [Related]
10. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
Bryant RJ; Oxley J; Young GJ; Lane JA; Metcalfe C; Davis M; Turner EL; Martin RM; Goepel JR; Varma M; Griffiths DF; Grigor K; Mayer N; Warren AY; Bhattarai S; Dormer J; Mason M; Staffurth J; Walsh E; Rosario DJ; Catto JWF; Neal DE; Donovan JL; Hamdy FC;
BJU Int; 2020 Apr; 125(4):506-514. PubMed ID: 31900963
[TBL] [Abstract] [Full Text] [Related]
11. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant prostate cancer from a Prospective Multicentre Registry.
Shah TT; Peters M; Eldred-Evans D; Miah S; Yap T; Faure-Walker NA; Hosking-Jervis F; Thomas B; Dudderidge T; Hindley RG; McCracken S; Greene D; Nigam R; Valerio M; Minhas S; Winkler M; Arya M; Ahmed HU
Eur Urol; 2019 Jul; 76(1):98-105. PubMed ID: 30638633
[TBL] [Abstract] [Full Text] [Related]
12. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
[TBL] [Abstract] [Full Text] [Related]
13. Identification of Potential miRNAs Biomarkers for High-Grade prostate cancer by Integrated Bioinformatics Analysis.
Foj L; Filella X
Pathol Oncol Res; 2019 Oct; 25(4):1445-1456. PubMed ID: 30367364
[TBL] [Abstract] [Full Text] [Related]
14. Transcriptome analysis of ankylosing spondylitis patients before and after TNF-α inhibitor therapy reveals the pathways affected.
Wang XB; Ellis JJ; Pennisi DJ; Song X; Batra J; Hollis K; Bradbury LA; Li Z; Kenna TJ; Brown MA
Genes Immun; 2017 Sep; 18(3):184-190. PubMed ID: 28835680
[TBL] [Abstract] [Full Text] [Related]
15. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.
Shalapour S; Font-Burgada J; Di Caro G; Zhong Z; Sanchez-Lopez E; Dhar D; Willimsky G; Ammirante M; Strasner A; Hansel DE; Jamieson C; Kane CJ; Klatte T; Birner P; Kenner L; Karin M
Nature; 2015 May; 521(7550):94-8. PubMed ID: 25924065
[TBL] [Abstract] [Full Text] [Related]
16. cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.
De Angelis R; Sant M; Coleman MP; Francisci S; Baili P; Pierannunzio D; Trama A; Visser O; Brenner H; Ardanaz E; Bielska-Lasota M; Engholm G; Nennecke A; Siesling S; Berrino F; Capocaccia R;
Lancet Oncol; 2014 Jan; 15(1):23-34. PubMed ID: 24314615
[TBL] [Abstract] [Full Text] [Related]
17. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent.
Accardo A; Salsano G; Morisco A; Aurilio M; Parisi A; Maione F; Cicala C; Tesauro D; Aloj L; De Rosa G; Morelli G
Int J Nanomedicine; 2012; 7():2007-17. PubMed ID: 22619538
[TBL] [Abstract] [Full Text] [Related]
18. Multiple myeloma with biclonal gammopathy accompanied by prostate cancer.
Kim NY; Gong SJ; Kim J; Youn SM; Lee JA
Korean J Lab Med; 2011 Oct; 31(4):285-9. PubMed ID: 22016684
[TBL] [Abstract] [Full Text] [Related]
19. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Serafini F; Cambria R; Vavassori A; Cattani F; Garibaldi C; Gherardi F; Ferrari A; Rocco B; Scardino E; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):26-34. PubMed ID: 20133085
[TBL] [Abstract] [Full Text] [Related]
20. Racial differences in risk of prostate cancer associated with metabolic syndrome.
Beebe-Dimmer JL; Nock NL; Neslund-Dudas C; Rundle A; Bock CH; Tang D; Jankowski M; Rybicki BA
Urology; 2009 Jul; 74(1):185-90. PubMed ID: 19428088
[TBL] [Abstract] [Full Text] [Related]
[Next]
